Increasing Body Mass Associated with Increasing Cancer Incidence and Mortality(11/19/2007) Researchers affiliated with the UK Million Women Study have reported that increasing body mass index (BMI) is associated with an increased risk of 10 specific types of cancer out of 17 evaluated. The details of this study appeared in an early on-line publication on November 6, 2007 in the British Medical Journal.
Little Evidence That Lycopene Reduces Cancer Risk(7/23/2007) According to a review conducted by the U.S. Food and Drug Administration (FDA), there is “no credible evidence” that lycopene reduces the risk of cancers such as prostate cancer, and “very limited evidence” that tomato consumption reduces risk. The review was published in the July 10,2007 issue of the Journal of the National Cancer Institute.
Flavonols May Reduce Risk of Pancreatic Cancer(5/7/2007) According to the results of a study presented at the 2007 annual meeting of the American Association for Cancer Research (AACR), higher intake of flavonols (compounds found in many plant-based foods) may reduce the risk of developing pancreatic cancer, particularly in smokers.
Increased Vitamin D Intake Reduces Risk of Pancreatic Cancer(9/20/2006) Researchers at Northwestern University, Harvard Medical School, and the Dana-Farber Cancer Institute have reported that persons who consumed more than 600 IU of vitamin D a day had a 41% reduction in the incidence of pancreatic cancer compared to those who consumed less than 150 units.
Endoscopic Ultrasound Accurately Rules Out Pancreatic Cancer(10/25/2005) Researchers from the H. Lee Moffitt Center and Research Institute and the University of California at Irvine have reported that endoscopic ultrasound (EUS) is highly specific for the diagnosis of pancreatic cancer with a negative predictive value of 100%.
Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers(8/4/2008) Researchers affiliated with the Cancer Programs, American College of Surgeons, recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic cancers. The results of this study were published in the July 2008 issue of the Archives of Surgery.
Gemzar® Improves Survival in Early Pancreatic Cancer(6/9/2008) Researchers from Germany have reported that adjuvant Gemzar® (gemcitabine) significantly improves disease-free and overall survival of patients with early pancreatic cancer. The details of this study were reported in a late-breaking abstract at the 2008 meeting of the American Society of Clinical Oncology May 30 to June 2 in Chicago.
Abraxane®/Gemzar® Promising in Pancreatic Cancer(4/24/2008) Researchers from the Scottsdale Clinical Research Institute in Arizona have reported that Abraxane® (paclitaxel) and Gemzar® (gemcitabine) appeared promising for the treatment of advanced pancreatic cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research, April 12-16, 2008 in San Diego.
Addition of Gemzar® in Early Pancreatic Cancer May Modestly Improve Survival(3/10/2008) A multicenter U.S. and Canadian trial has shown that the addition of Gemzar® (gemcitabine) to 5-fluorouracil may modestly improve survival among patients undergoing surgery for early pancreatic cancer. The results of this Phase 3 randomized trial were published in the March 5, 2008 issue of the Journal of the American Medical Association.
Surgery Underused for Early Pancreatic Cancer(10/30/2007) Researchers from Northwestern University have determined that 38% of patients with early stage pancreatic cancer with no identifiable contraindications are not receiving appropriate surgery. The details of this study appeared in the August, 2007 issue of the Annals of Surgery.
Normalization of N-telopeptide Associated with Improved Survival from Bone Metastasis Treated with Bisphosphonates(6/25/2008) Researchers involved in a multicenter international trial have reported that normalization of N-telopeptide of type I collagen (NTX) levels is associated with skeletal-related events and survival among patients with bone metastases from solid tumors treated with Zometa® (zoledronic acid) or Aredia® (pamidronate). These results were published in the July 1, 2008 issue of Cancer.
Abraxane®/Gemzar® Promising in Pancreatic Cancer(4/24/2008) Researchers from the Scottsdale Clinical Research Institute in Arizona have reported that Abraxane® (paclitaxel) and Gemzar® (gemcitabine) appeared promising for the treatment of advanced pancreatic cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research, April 12-16, 2008 in San Diego.
Addition of Erbitux® Does Not Improve Outcomes in Pancreatic Cancer(4/14/2008) Researchers from Italy have reported that the addition of Erbitux® (cetuximab) to Gemzar® (gemcitabine) and Platinol® (cisplatin) does not improve outcomes compared with chemotherapy only in advanced pancreatic cancer. These results were published in the January 2008 issue of Lancet Oncology.
Different Chemotherapy Combinations Effective in Pancreatic Cancer(11/16/2007) A multi-center randomized trial comparing three different palliative chemotherapy regimens for patients with advanced pancreatic cancer has found that all three regimens were equally effective but with differing side effects. The details of this study appeared in an early on-line publication in the Annals of Oncology on October 24, 2007.
Addition of Tarceva® to Gemzar® Improves Survival in Pancreatic Cancer(5/9/2007) An international randomized trial has demonstrated that the addition of Tarceva® (erlotinib) to Gemzar® (gemcitabine) improves survival in patients with advanced pancreatic cancer. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on April 26, 2007.
Normalization of N-telopeptide Associated with Improved Survival from Bone Metastasis Treated with Bisphosphonates(6/25/2008) Researchers involved in a multicenter international trial have reported that normalization of N-telopeptide of type I collagen (NTX) levels is associated with skeletal-related events and survival among patients with bone metastases from solid tumors treated with Zometa® (zoledronic acid) or Aredia® (pamidronate). These results were published in the July 1, 2008 issue of Cancer.
Different Chemotherapy Combinations Effective in Pancreatic Cancer(11/16/2007) A multi-center randomized trial comparing three different palliative chemotherapy regimens for patients with advanced pancreatic cancer has found that all three regimens were equally effective but with differing side effects. The details of this study appeared in an early on-line publication in the Annals of Oncology on October 24, 2007.
Gemzar® Plus Second Chemotherapy Agent Provides Small Survival Benefit in Advanced Pancreatic Cancer(10/8/2007) Researchers from France have reported that the combination of Gemzar® (gemcitabine) with a second chemotherapy agent provides a small but significant improvement in survival compared with Gemzar only in the treatment of metastatic pancreatic cancer. The details of this metaanalysis were reported in the October, 2007 issue of Drugs and Aging.
Weekly Taxol®, Eloxatin®, Leucovorin and 5-FU Promising for Metastatic Pancreatic Cancer(3/23/2007) Researchers from the Seattle Cancer Treatment and Wellness Center have reported significant and prolonged responses in 7 patients with metastatic pancreatic cancer treated with weekly Taxol (paclitaxel), Eloxatin, leucovorin, and 5-FU for 12 weeks. The details of this small phase II study were presented at the 2007 Gastrointestinal Symposium in Orlando Florida sponsored by the American Society of Clinical Oncology.
Vaccine May Extend Survival in Pancreatic Cancer(12/1/2005) Researchers from the Johns Hopkins Kimmel Cancer Center have reported promising results of a killed allogeneic pancreatic cell vaccine for the adjuvant treatment of resected pancreatic cancer.
Patient Home
